Abstract Transcranial magnetic stimulation (TMS) has served as an important technological breakthrough in the field of the physiology of movement disorders over the last three decades. TMS has grown popular owing to the ease of application as well as its painless and noninvasive character. The technique has provide important insights into understanding the pathophysiology of movement disorders, particularly Parkinson's disease and dystonia. The basic applications have included the study of motor cortex excitability, functioning of excitatory and inhibitory circuits, study of interactions between sensory and motor systems, and the plasticity response of the brain. TMS has also made important contributions to understanding the response to treatments such as dopaminergic medications, botulinum toxin injections, and deep brain stimulation surgery. This review summarizes the knowledge gained to date with TMS in Parkinson's disease and dystonia, and highlights the current challenges in the use of TMS technology.
Introduction
Transcranial magnetic stimulation (TMS) is a safe and noninvasive method of stimulating the cortical neurons [1] . More than three decades ago, Merton and Morton [2] developed a technique known as transcranial electrical stimulation that stimulated the motor areas of the human brain through intact scalp. In this technique a brief, high-voltage electric shock was delivered to the primary motor cortex (M1), which in turn produced a brief, relatively synchronous muscle response, the motor-evoked potential (MEP) [2] . Since this technique was painful, a few years later, Barker et al. [3] refined the stimulation method and showed it was possible to stimulate the brain with painless magnetic pulses. This refined technique was called transcranial magnetic stimulation (TMS), where a magnetic field generator sends a large short-duration current through an induction coil placed on the scalp. This large current creates a magnetic field that is perpendicular to the coil (Faraday's law), and this passes through the skull and stimulates the underlying brain parallel to the coil [3] . Since most of the intracortical horizontally oriented neural elements near the cortical surface are interneurons, TMS is more likely to activate pyramidal cells transsynaptically [4] . The motor cortex when stimulated with sufficient intensity sends descending volleys along the corticospinal pathway, and the resulting activation of muscles can be recorded by surface electromyography [1] (Fig. 1) .
Several TMS paradigms have since been developed to investigate the physiology of the motor system. These paradigms range from simple measurement of motor cortex excitability and assessment of central motor conduction time to complex examples of applying paired stimuli to study the inhibitory and excitatory circuits, measurement of interaction of peripheral stimulus with central motor cortex stimulation, and measurement of motor cortex plasticity. These paradigms, discussed in subsequent sections, have been used widely to understand better the pathophysiology of movement disorders [5] . Furthermore TMS has provided substantial insight into the mechanisms underlying therapy for movement disorders, such as dopaminergic medications for treatment of Parkinson's disease (PD), botulinum toxin injections for treatment of dystonia, and deep brain stimulation (DBS) for treatment of PD and dystonia. The main focus of this review is to discuss the role of TMS in revealing potential mechanisms.
Standard TMS Paradigms and Basic Concepts
Physiological activity in the motor cortex depends on the balance between excitatory and inhibitory influences. TMS can test different excitatory and inhibitory circuits in the brain on the basis of the individual stimulus parameters [6, 7] . Table 1 summarizes the major TMS paradigms and the effects on PD and dystonia. Single-pulse TMS when applied to the motor cortex determines the motor threshold that is believed to represent a measure of membrane excitability of pyramidal neurons [8] . Although there is considerable information on these circuits, far less is understood about how these circuits are related to each other and how they interact [6] . Pairedpulse TMS studies have established paradigms for at least two types of intracortical inhibition, referred to as short-interval intracortical inhibition (SICI) [9] and long-interval intracortical inhibition (LICI) [10] . SICI is a complex cortical phenomenon that encompasses study of different inhibitory circuits at different interstimulus intervals (ISIs) [11, 12] . SICI involves a subthreshold conditioning stimulus followed by a suprathreshold test stimulus applied to the primary motor cortex (M1) using a figure-of-eight TMS coil. The MEPs recorded from peripheral surface electromyography (EMG) muscles are found to be inhibited at ISIs of 1-6 ms. LICI is elicited by a suprathreshold conditioning pulse followed by a test pulse applied at an ISI of approximately 50-200 ms [13, 14] . "Silent period" refers to a period of suppression of voluntary muscle contraction which is elicited by application of 1 TMS pulses applied to the motor cortex, 2 motor cortex interneurons that mediate short-interval intracortical inhibition (SICI) and long-interval intracortical inhibition (LICI), 3 sensory cortex neurons that mediate sensorimotor integration such as short-latency afferent inhibition (SAI) and long-latency afferent inhibition (LAI), 4 Corticospinal output neurons that generate motor evoked potentials are activated transsynaptically by the TMS pulse, 5 sensory stimuli from the periphery are projected to sensory cortex by the thalamus, 6 motorevoked potential (MEP) recording from the first dorsal interosseus muscle, 7 median nerve stimulation at the periphery that forms the conditioning stimulus. b Examples of TMS paradigms. The first column shows sensorimotor integration (SAI and LAI) and motor cortex inhibition (SICI and LICI) and the second column shows sensorimotor plasticity obtained with a paired associative stimulation (PAS) protocol. The traces show average MEP recordings with a test pulse alone (TS) or preceded by median nerve stimulation delivered at an interstimulus interval (ISI) of 20 ms (MNS20) or 200 ms (MNS200) or when preceded by a conditioned stimulus delivered to the motor cortex at an ISI of 2 ms (CS2) or 100 ms (CS100) For the PAS protocol, 90 pairs of median nerve stimulation preceding the TMS pulse by 25 ms are delivered suprathreshold TMS pulses. We have found evidence that LICI is likely related to the silent period [14] . LICI has been shown to be abnormal in PD (increased) [15] and dystonia (decreased) [16] . Among the excitatory circuits for the motor system, intracortical facilitation is a phenomenon commonly tested using protocols similar to those used for testing SICI [9] . Intracortical facilitation involves a subthreshold conditioning stimulus followed by a suprathreshold test stimulus at an ISI of 8-30 ms. Similarly to SICI, intracortical facilitation also occurs in the cortex [17] rather than subcortical structures, but intracortical facilitation is mediated by neuronal populations separate from SICI [17, 18] . In addition to motor system excitability, the interaction of sensory and motor systems can be examined with TMS paradigms of short-latency afferent inhibition (SAI) and longlatency afferent inhibition (LAI). In these paradigms, the effects of peripheral sensory stimulation on motor cortex excitability are assessed with application of a sensory stimulus such as median nerve stimulation followed by a test stimulus over the contralateral motor cortex. Inhibition of the test MEP is most consistent at two distinct ISIs of approximately 20 ms and 200 ms [19] . At short latencies (less than 40 ms) the contralateral S1 and secondary somatosensory cortex (S2) are primarily activated, whereas at longer latencies (more than 40 ms) there is more widespread activation of sensory areas, including S1, bilateral S2, and the contralateral posterior parietal cortex [20, 21] . SAI also exhibits a somatotopic organization [22] such that cortical inhibition due to electrical stimulation of a digit near a target muscle (i.e., homotopic) is stronger than cortical inhibition due to stimulation of a digit distant from a target muscle (i.e., heterotopic) [23] .
Furthermore, interactions between the cerebellum and motor cortex can be examined with magnetic stimulation of the cerebellum. Stimulation using a double-cone coil followed by stimulation of the contralateral motor cortex at an ISI of 5-7 ms has been found to inhibit the MEPs. This is referred to as cerebellar inhibition [24, 25] . In this inhibitory circuit, cerebellar stimulation with TMS probably activates Purkinje cells in the cerebellar cortex, leading to inhibition of deep cerebellar nuclei such as the dentate nucleus, which then projects to the motor cortex via a disynaptic excitatory pathway passing through the ventral thalamus [26, 27] . Cerebellar inhibition has been found to be normal in essential tremor [28] ; however, it is reduced in PD [29] .
Finally, the plasticity response of the neuronal synapse (i.e., the ability of a neuron to modify its synaptic structure or function in response to stimuli that outlast the stimulation period) can be examined with TMS [30, 31] . Long-term potentiation (LTP), generally defined as a long-lasting increase in synaptic strength, and long-term depression (LTD), a decrease in synaptic strength, are examples of synaptic plasticity that represent key mechanisms for adaptive motor control [32] . Protocols such as intermittent theta burst stimulation, high-frequency repetitive TMS (rTMS), and PAS25 (25 ms between peripheral nerve stimulation and motor cortex stimulation) are considered LTP-like protocols, whereas continuous theta burst stimulation, low-frequency rTMS, and PAS10 (10 ms between peripheral nerve stimulation and motor cortex stimulation) are considered LTD-like protocols [33] .
Although TMS paradigms are well established, they have been criticized for exhibiting wide variability in effects. Several factors have been identified that contribute to this variation and should be kept in consideration when interpreting the physiological effects. These factors are either extrinsic factors (cortical target, frequency, intensity, duration, number of sessions) or patient-based intrinsic factors (genetic polymorphisms of neurotransmitters and receptors, hormonal level, attention level, spontaneous variation in cortical excitability, fatigue of subjects, individual variability and symptoms, state of medication treatment) [34] . Another important limitation of the current round or focal figure-of-eight coils is the lack of ability to stimulate deep brain regions; however, with technological advances in coil configuration, this may likely change [1] . For example, an H coil with complex windings that permit a slower falloff of the intensity of the magnetic field with depth was recently introduced to allow stimulation of deep brain regions [35] . In another configuration, the windings of a coil were designed around an iron core rather than air, to focus the field and allow greater strength and depth of penetration [36] .
TMS in PD
Pathophysiology of PD Bradykinesia (slowness of voluntary movements) is a cardinal feature of PD. Simple reaction time tasks that involve subjects making the same response to a given stimulus on every trial have been found to be prolonged in PD [37] . The accuracy of movements, particularly if the movements have to be as fast as possible, is affected [38] . In one study, Cunnington et al. [39] asked patients to make a rapid sequence of finger movements from left to right by pressing buttons along a tapping board. When a TMS pulse was delivered to the supplementary motor area early in the interval between button presses, this slowed the process of next button press, indicating that supplementary motor area function is compromised in PD [39] . Although the corticomotoneuronal conduction time and motor thresholds are both normal in PD [40] , the slope of the relationship between stimulus intensity and response size when tested at rest is steeper than normal [41] . This implies that the distribution of cortical excitability is skewed towards higher than normal values, and it has been speculated to be an attempt on the part of the motor cortex to compensate for a slow recruitment of commands to move. Furthermore, TMS studies have shown abnormal excitability of cortical inhibitory circuits. The silent period is shorter and SICI is reduced in PD [15] . Again, reduced SICI could be a compensatory mechanism that allows the motor commands to have easier access to cortical output. Finally, sensory symptoms [42] and objective sensory deficits, especially diminished proprioception and kinesthesia [43, 44] , are well documented and considered to play an important role in the pathophysiology of PD. TMS studies have shown there is an abnormal sensorimotor integration in PD when measured with paired-pulse paradigms of SAI and LAI [45] .
Understanding the Physiological Effects of Dopaminergic Therapies
Levodopa therapy is the cornerstone therapy for motor symptoms in PD. Table 2 summarizes the TMS findings from treatment studies of medication and DBS for both PD and dystonia.
Levodopa therapy in PD has been found to affect motor cortex excitability, by improving the silent period and SICI [15] . Levodopa has also been shown to influence the connectivity between the dorsal premotor cortex and the primary cortex. In early-stage PD patients, 1-Hz rTMS delivered to the dorsal premotor cortex was found to restore a deficient intracortical inhibition of the primary motor cortex (M1) seen in the presence of levodopa [53] . The inhibitory circuit in this case was measured with a paired-pulse protocol where a subthreshold conditioning stimulus was followed by a suprathreshold test stimulus delivered to M1 at an ISI of 5 ms. The authors of the study concluded that 1-Hz rTMS to the dorsal premotor cortex modulates M1 intracortical circuits. TMS studies have also shown that dopaminergic therapies modulate sensorimotor integration in PD. Sailer et al. [45] found that SAI is unaffected by PD, but is reduced in the presence of dopaminergic medication, whereas LAI is reduced regardless of the medication status, suggesting thereby that SAI plays a role in the pathophysiology of dopaminergic complications and LAI probably reflects a nondopaminergic manifestation of the disease.
Levodopa therapy when administered for prolonged periods of 5-10 years [54] , is associated with motor fluctuations and dyskinesias [55] . Chronic "pulsatile" nonphysiological stimulation of dopamine receptors located on the striatal neurons has been shown to induce postsynaptic signaling abnormalities and an abnormal plasticity response [56] . A recent TMS study examined the plasticity response and the effects of acute challenge with nonphysiological dopamine in three groups of PD patients: patients who were stable responders to levodopa, patients who had motor fluctuations but no dyskinesia, and patients who had motor fluctuations as well as dyskinesia. They found that the LTP-and LTD-like plasticity responses were normal in the first group, LTD was impaired in the second group, and both types of plasticity response were absent in the third group. When an immediate levodopa challenge was provided, there was worsening of LTD in all three groups, and worsening of LTP in the second group, suggesting an adverse effect of nonphysiological dopamine on the plasticity response [46•]. These findings were suggested to be related to a persistent dysfunction of the intracellular signaling DBS deep brain stimulation, GPi globus pallidus pars interna, LTD long-term depression, LTP long-term potentiation, STN subthalamic nucleus cascade in the striatum that resulted from repeated exposure to nonphysiological surges in synaptic dopamine involved in the maintenance of both forms of plasticity.
TMS Insight into DBS Effects in PD
Since the 1990s, DBS has been touted as an efficacious treatment for motor fluctuations and medication-refractory tremors in PD. The subthalamic nucleus (STN) and the globus pallidus pars interna (GPi), are two preferred targets for stimulation, and they both have shown equivalent benefits [57] . STN activity in PD is characterized by augmented synchrony of neuronal firing, loss of specificity of the receptive fields, and increased firing rates with bursting activity [58, 59] . A pathological drive from the STN is hypothesized to disrupt the activity of the substantia nigra pars reticulata, GPi, globus pallidus pars externa, pedunculopontine nucleus, thalamus, and various cortical areas [60, 61] . TMS studies have shown STN DBS to modulate the activity of the motor cortex. Several authors following low-frequency STN stimulation have recorded evoked potentials from scalp electrodes at short (2-8 ms) and medium (18-25 ms) latencies [62, 63] . These potentials are evoked at these latencies if the current induced by the TMS coil is delivered in the anterior-posterior direction [64] . These potentials likely relate to short-latency antidromic stimulation of corticosubthalamic projections and the medium-latency facilitatory basal ganglia-thalamocortical interactions following STN stimulation. On the other hand, application of a TMS pulse to the motor cortex has been found to change the firing rate of STN neurons [65] and the oscillatory activity of the STN [66] . Motor cortex excitability after STN DBS has been found to be changed only at specific time intervals. This was well explained when TMS studies found STN DBS to increase the motor cortical inhibition yet there were no effects on the motor threshold or MEP amplitude [47, 48] . Cunic et al. [47] found bilateral GPi DBS to normalize the "silent period" that was abnormally shortened in PD [67] , whereas STN stimulation under similar experimental conditions had little effect on the silent period. The disparity between the effects of STN DBS and GPi DBS on the silent period was suggested to be related to the antidyskinetic effects of GPi stimulation.
Prior studies in PD had found an abnormal SAI in the presence of dopaminergic medications only and an abnormal LAI regardless of medication status probably related to nondopaminergic features of PD [45] . In patients with chronic STN DBS, SAI and LAI were found to be reduced in the with medication-no stimulation state; however when the stimulators were turned on, these abnormalities normalized. The inference of the study was STN DBS in PD restores a deficient sensorimotor integration [49] . In a subsequent longitudinal study, these modulatory effects of STN DBS were demonstrated only at 6 months and not at 1 month. These findings suggested chronic stimulation is important in elicitation and potentially in maintenance of physiological changes [50•] .
TMS in Dystonia

Pathophysiology of Dystonia
The term "dystonia" is used to describe a syndrome characterized by prolonged muscle contractions, causing twisting movements and abnormal postures of the affected body part(s). Dystonia may be focal, segmental, or generalized according to the different body parts affected [68, 69] . During standard clinical MRI, typical interpretation by a neuroradiologist of T1, T2, and other imaging does not reveal any structural changes in primary dystonia. However, when TMS is used, these physiological studies have identified several important functional abnormalities [70] .
The pathophysiological substrate of dystonia comprises three general abnormalities which relate to each other. There is strong evidence to show that there is a loss of inhibition at the level of the spinal cord, brainstem, and cortex, which explains the excess of movement and the overflow phenomena seen in dystonia [70] . The failure of SICI in focal hand dystonia suggests that there might well be a cortical abnormality of intracortical inhibitory neurons in dystonia [40, 71] . Similar cortical abnormality was suggested by a study of the silent period, which was found to be abnormally shortened in patients with writer's cramp [16] . These alterations in inhibitory circuits are nonspecific in that they have been observed in a wide variety of other neurological conditions, including psychogenic dystonia [72, 73] . In dystonia, an abnormal intracortical inhibition is found to be present in both hemispheres despite unilateral symptoms and asymptomatic body parts [70] . It is reasonable to assume that abnormalities in the asymptomatic body parts reflect compensatory changes to prevent a clinical manifestation of dystonia. However, some argue that this seems unlikely since the abnormalities are generally the same as those in the symptomatic body parts and are in the direction that leads to motor dysfunction.
The second major theme in the pathophysiology of dystonia is a defect in sensory function or in "sensorimotor integration" [74] . Sensory dysfunction may clinically show only minor findings such as ill-defined bodily feelings (discomfort, pain, or kinesthetic sensations) [75] ; however, these are believed to drive the motor system in an abnormal direction. Patients with focal dystonia have difficulty in discriminating sensory stimuli in both spatial and temporal domains [76] . These alterations may be related to a deranged somatotopic representation in the sensory cortex as revealed by neurophysiological and neuroimaging studies [77] [78] [79] . The basal ganglia and cerebellum are thought to play an important role in the sensory and perceptual defects seen in dystonia. The basal ganglia are believed to participate in sensory gating and filtering out the nature of sensory information that is "passed" to the motor cortex [80] . TMS studies found that although SAI and LAI were comparable to those in healthy controls, in focal dystonia patients [81, 82] there was an increased homotopic digital SAI, during flexion of the second digit. This suggests that this process was a compensatory act to diminish overflow during movement [23] . Unlike the basal ganglia, which receive sensory information indirectly, the cerebellum is a direct recipient of sensory input from the spinal cord [83] . Patients with writer's cramp performed much more slowly and less efficiently than healthy control subjects in a reaching task known to involve the cerebellum where a visuomotor conflict was generated by a random deviation (−40°to 40°) in the direction of movement of the mouse/cursor [84] .
Third, in primary dystonia there is a derangement of plasticity response shown as an exaggerated responsiveness of the motor and sensory cortex to TMS conditioning protocols [85, 86] . With use of paired associative stimulation (PAS) protocols in patients with writer's cramp, both LTP-like facilitatory and LTD-like inhibitory effects on TMS-evoked MEPs have been found to be enhanced [85, 87] . An important feature of PAS-induced associative plasticity is the spatial specificity of the recorded MEPs from the target muscles. This has been seen to be lost in patients with writer's cramp, in that the PAS tends also to change the cortical excitability of nearby muscle representations [85, 88] . Hubsch et al. [84] applied rTMS pulses to either excite or inhibit the cerebellar cortex in writer's cramp patients, before the sensorimotor plasticity response of the motor cortex could be tested with the PAS protocol. They found cerebellar cortex excitation and inhibition were both ineffective in modulating sensorimotor plasticity. Another paradigm for study of plasticity involving use of theta burst stimulation showed a loss of response even in nonmanifesting DYT1 gene carriers, suggesting this may have represented an important endophenotypic trait that predisposes to a subsequent development of dystonia [89] .
TMS Insight into Botulinum Toxin Injection Effects in Dystonia
Botulinum toxin type A (BT-A) is widely used medication for treatment of primary dystonia. The clinical benefits primarily depend on the toxin's peripheral action of inhibiting acetylcholine release from the presynaptic neuromuscular terminals, thus weakening contraction of the muscle fibers responsible for excessive involuntary movements. Although clinical improvement mostly parallels the weakness caused by injections, the clinical benefits often seem out of proportion to the weakness, suggesting an additional, possibly central effect of BT-A [90, 91] . In theory, BT-A that is injected locally could produce central effects directly, by being transported into central structures, or indirectly, by altering the central sensorimotor integration through a peripheral mechanism [92] . Many experimental studies have provided support for a central action of BT-A. First, BT-A when injected into skeletal muscles acts at the intrafusal as well the extrafusal neuromuscular junction. The toxin blocks the gamma motor endings of jaw muscles in the rat, reducing the spindle afferent discharge without altering the muscle tension [93] . Then there is evidence that intramuscularly injected BT-A influences the spinal cord circuitry. Weigand et al. [94] , in a retrograde-tracing study showed that approximately 48 h after injection of radiolabeled BT-A into the cat gastrocnemius muscle, a distal-proximal gradient of radioactivity developed first in the sciatic nerve, then in the ipsilateral spinal ventral roots, and ultimately in the spinal cord segments innervating the muscle into which BT-A had been injected.
In humans, with the help of TMS, the central effects of BT-A became further elucidated. Pauri et al. [95] investigated changes in MEPs in patients with lower limb spasticity requiring BT-A injections in the calf muscles. They found that when TMS was applied to the leg area of the cortex, the MEP latency and central conduction time increased significantly in the muscles into which BT-A had been injected roughly 2 weeks after treatment in parallel to clinical benefits. They attributed these findings to a central change in spinal motor neuron responsiveness to descending impulses from the corticospinal tracts. TMS studies have also shown that after BT-A injections, there are changes in cortical organization. In a study of writer's cramp patients, Byrnes et al. [96] delivered TMS before and after BT-A injections and mapped the topography of the primary motor cortex projections to the upper limb muscles. They found concurrent to clinical improvement, the cortical maps had a distorted shape with extended lateral borders that became reversed with BT-A injections. As the clinical benefits with BT-A wore off, the cortical maps returned to their original topography, suggesting BT-A may have transiently modulated the abnormal afferent inputs from the periphery, explaining these central effects.
A similar study was conducted in patients with upper limb dystonia to investigate the before and after effects of BT-A on intracortical inhibitory circuits of the primary motor cortex [97] . Before treatment, patients showed reduced intracortical inhibition, which returned to values seen in normal subjects 1 month after the injection. However, after 3 months of BT-A injections, the values of intracortical inhibition dropped again to pretreatment levels. This study suggests that BT-A can transiently modify the excitability of the motor cortical areas by reorganizing inhibitory and excitatory intracortical circuits [97] . In patients with blepharospasm, BT-A has also been shown to reduce the abnormally enhanced plasticity response of the trigeminal blink reflex [98] . These effects have again been explained by the modulation of the afferent input from the muscle spindles by the injections [93] . Kojovic et al. [51•] applied the PAS protocol to 12 patients with cervical dystonia and studied the plasticity response of primary motor cortex before, 1 month after, and 3 months after botulinum toxin-A injections administered to the neck muscles. Before botulinum toxin-A injections, the PAS protocol found MEPs in the hand muscles to be facilitated, and this was seen to be abolished 1 month after the injections, with a partial recovery seen after 3 months. These effects of botulinum toxin-A on plasticity were again attributed to the modulation of afferent input from the neck.
TMS Insight into DBS Effects in Dystonia
Several medical therapies have been tried for treatment of primary dystonias, with limited efficacy, leaving many patients with a profound disability and the related stigma. DBS of the globus pallidus has been considered a well-established treatment for medication-refractory primary generalized dystonia [99] . The first reports of DBS success in dystonia were published a decade ago [100] , and recent long-term results demonstrate that benefits are maintained for more than 10 years after surgery [101, 102] . Although mean postoperative results for clinical measures have generally been encouraging, there is a wide range (20-95 % on dystonia scores) of clinical improvement. Many factors have been considered to explain this wide range of outcome, including the use of a precise target, which is posteroventral GPi stimulation for the greatest overall effect, the presence of short-duration disease [103, 104] , and increase in GPi-stimulated volumes, which all predict better outcome [105] . There is emerging evidence to show the STN is an alternative target for dystonia, with benefits in a similar range [106] .
Finally, in contrast to the almost immediate effects of DBS seen in most PD symptoms, it often takes several months before clinical benefits are observed in dystonia [99, 100] . In a study of time course changes with GPi DBS, turning on GPi DBS in parallel with clinical improvement was found to progressively reverse the spinal and brainstem disinhibition, suggesting a gradual neural reorganization towards a more normal physiological pattern [107, 108] . Similarly, the changes of LTP-like synaptic plasticity on application of the PAS protocol were reduced below normal after surgery and required at least 6 months before showing any trend towards normalization, although SICI became normalized at 1 month [52•].
Summary and Conclusions
TMS is a noninvasive physiological tool for investigation of excitatory and inhibitory changes of relevance to the pathophysiology of PD and dystonia and can be used to uncover various underlying treatment mechanisms. TMS studies have shown levodopa and DBS therapy in PD has specific modulatory effects on the motor cortex excitability and the interaction of the sensory and motor systems. Furthermore, longterm administration of pulsatile levodopa results in a negative effect on the plasticity response of the motor cortex. BT-A, although injected into peripheral muscles in dystonia, has clear central effects on motor cortex excitability and plasticity. Finally, motor cortex plasticity demonstrates a time-dependent response to DBS treatment in dystonia. Despite this growth in knowledge with TMS, one of the main challenges to date has been the extreme variability in response patterns and the lack of ability to probe deeper structures of the brain. To improve on the sensitivity and specificity of the research findings, future studies should apply TMS paradigms to large, well-characterized, and homogeneous disease populations. With the advent of stimulation patterns coupled with novel stimulation coils, it will become probable to investigate deeper brain circuits that are of relevance to movement disorders. Researchers will likely continue to use TMS to understand disease processes, brain circuitries, and treatment interventions.
